Claiming desmopressin therapeutic equivalence in children requires pediatric data: a population PKPD analysis.
Robin MicheletLien DosscheCharlotte Van HerzeeleJan Van BocxlaerAn VermeulenJohan Vande Wallenull nullPublished in: European journal of clinical pharmacology (2017)
A new indirect response model for desmopressin was constructed and validated, using a previously built pharmacokinetic model and additional pharmacodynamic data. In order to draw solid conclusions regarding the efficacy and safety of desmopressin in children, pharmacokinetics and pharmacodynamics data should be analyzed together. This study adds proof to potential differences in pediatric and adult pharmacokinetic and pharmacodynamic properties of desmopressin and exemplifies the need for pediatric clinical trials, not only for every new drug but also for every new formulation.